Slingshot members are tracking this event:

Novartis drug Afinitor receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process

Additional Information

Additional Relevant Details The EU approval of Afinitor was based on efficacy and safety data from a pivotal Phase III study (RADIANT-4) evaluating Afinitor versus placebo in patients with advanced, progressive, well-differentiated nonfunctional NET of GI or lung origin. Results showed that Afinitor reduced the risk of disease progression by 52% (hazard ratio = 0.48; 95% confidence interval [CI], 0.35-0.67; p<0.00001) compared to placebo. The data also showed Afinitor increased median progression-free survival (PFS) by 7.1 months: median PFS by central review was 11.0 months (95% CI, 9.2-13.3) in the Afinitor arm and 3.9 months (95% CI, 3.6-7.4) in the placebo arm[3].In the pivotal trial, the most common treatment-related, all-grade adverse events (AEs) (incidence >=20%) for Afinitor and placebo, respectively, were stomatitis (63% vs 19%), diarrhea (31% vs 16%), fatigue (31% vs 24%), infections (29% vs 4%), rash (27% vs 8%) and peripheral edema (26% vs 4%). The most common treatment-related grade 3/4 AEs (incidence >=5%) for Afinitor versus placebo were stomatitis (9.0% vs 0.0%), diarrhea (7.0% vs 2.0%) and infections (7.0% vs 0.0%)[3].
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 02, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Advanced Gastrointestinal, Lung Neuroendocrine Tumors, Net